Multivalent Carbonic Anhydrases Inhibitors.
CA isoforms
carbonic anhydrases
inhibitors
multifunctionnal scaffold
multivalency
multivalent
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
28 Oct 2019
28 Oct 2019
Historique:
received:
03
10
2019
revised:
23
10
2019
accepted:
24
10
2019
entrez:
31
10
2019
pubmed:
31
10
2019
medline:
31
3
2020
Statut:
epublish
Résumé
Biomolecular recognition using a multivalent strategy has been successfully applied, this last decade on several biological targets, especially carbohydrate-processing enzymes, proteases, and phosphorylases. This strategy is based on the fact that multivalent interactions of several inhibitory binding units grafted on a presentation platform may enhance the binding affinity and selectivity. The zinc metalloenzymes carbonic anhydrases (CAs, EC 4.2.1.1) are considered as drug targets for several pathologies, and different inhibitors found clinical applications as diuretics, antiglaucoma agents, anticonvulsants, and anticancer agents/diagnostic tools. Their main drawback is related to the lack of isoform selectivity leading to serious side effects for all pathologies in which they are employed. Thus, the multivalent approach may open new opportunities in the drug design of innovative isoform-selective carbonic anhydrase inhibitors with biomedical applications.
Identifiants
pubmed: 31661796
pii: ijms20215352
doi: 10.3390/ijms20215352
pmc: PMC6862271
pii:
doi:
Substances chimiques
Carbonic Anhydrase Inhibitors
0
Dendrimers
0
Isoenzymes
0
Poly(amidoamine)
0
Polyamines
0
Gold
7440-57-5
Carbonic Anhydrases
EC 4.2.1.1
Zinc
J41CSQ7QDS
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Agence Nationale de la Recherche
ID : ANR-10- LABX-05-01
Organisme : Ligue Contre le Cancer
ID : Comité des Pyrénées Orientales
Références
ACS Nano. 2010 Aug 24;4(8):4559-64
pubmed: 20731439
Adv Drug Deliv Rev. 2012 Feb;64(2):190-9
pubmed: 21397647
Chemistry. 2014 Sep 8;20(37):11616-28
pubmed: 25081380
J Am Chem Soc. 2008 Dec 3;130(48):16130-1
pubmed: 18989963
Eur Phys J E Soft Matter. 2013 May;36(5):48
pubmed: 23677447
Expert Opin Drug Discov. 2019 Nov;14(11):1175-1197
pubmed: 31436118
J Biophotonics. 2011 Jan;4(1-2):64-73
pubmed: 20196029
ACS Appl Mater Interfaces. 2018 May 30;10(21):17792-17808
pubmed: 29733576
J Control Release. 2005 Jan 20;102(1):23-38
pubmed: 15653131
Org Biomol Chem. 2015 Jul 21;13(27):7445-51
pubmed: 26058669
Org Biomol Chem. 2015 Oct 21;13(39):9894-906
pubmed: 26338715
ACS Nano. 2010 Oct 26;4(10):5887-96
pubmed: 20863096
Bioorg Med Chem Lett. 2003 Aug 18;13(16):2759-63
pubmed: 12873509
Chemistry. 2017 Dec 19;23(71):17867-17869
pubmed: 28892198
Bioorg Med Chem. 2015 Nov 1;23(21):6794-8
pubmed: 26476668
J Med Chem. 2012 Aug 9;55(15):6776-83
pubmed: 22775345
Med Chem. 2012 Jul;8(4):753-68
pubmed: 22530907
Org Biomol Chem. 2015 Jun 21;13(23):6453-7
pubmed: 25976058
Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84
pubmed: 15664816
Bioorg Med Chem Lett. 2014 Apr 15;24(8):2002-7
pubmed: 24581919
Chemistry. 2017 May 17;23(28):6788-6794
pubmed: 28225196
Chemistry. 2015 Jul 13;21(29):10306-9
pubmed: 25965260
Chem Rec. 2019 Apr 17;:null
pubmed: 30993894
Expert Opin Drug Discov. 2017 Jan;12(1):61-88
pubmed: 27783541
J Enzyme Inhib Med Chem. 2016 Dec;31(6):946-52
pubmed: 26235915
J Enzyme Inhib Med Chem. 2016;31(3):345-60
pubmed: 26619898
J Med Chem. 2015 May 14;58(9):4039-45
pubmed: 25849626